J. Kent

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

R. Petrak, B. Harting, D. Vais, 2020, Clinical and translational science.

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2

R. Petrak, B. Harting, D. Vais, 2020, medRxiv.

AB0867 Pegloticase re-treatment after a gap in therapy: data from two phase iii trials and an open-label extension study

M. Soubrier, A. Tournadre, B. LaMoreaux, 2017 .